{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:21:45Z","timestamp":1780392105584,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04959-5","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:36:34Z","timestamp":1776720994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast"],"prefix":"10.1007","volume":"17","author":[{"given":"Xavier","family":"Catteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Fallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Charry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"De Caluw\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"3","key":"4959_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210263","volume":"21","author":"X Catteau","year":"2019","unstructured":"Catteau X, Simon P, Jondet M, Vanhaeverbeek M, No\u00ebl JC. Quantification of stromal reaction in breast carcinoma and its correlation with tumor grade and free progression survival. PLoS One. 2019;21(3):e0210263. https:\/\/doi.org\/10.1371\/journal.pone.0210263.","journal-title":"PLoS One"},{"key":"4959_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-014-0196-6","volume":"22","author":"X Catteau","year":"2014","unstructured":"Catteau X, Simon P, No\u00ebl JC. Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study. Diagn Pathol. 2014;22:196. https:\/\/doi.org\/10.1186\/s13000-014-0196-6.","journal-title":"Diagn Pathol"},{"issue":"9","key":"4959_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"1","author":"P Gascard","year":"2016","unstructured":"Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;1(9):1002\u201319. https:\/\/doi.org\/10.1101\/gad.279737.116.","journal-title":"Genes Dev"},{"issue":"6","key":"4959_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/emmm.201000073","volume":"2","author":"A Toullec","year":"2010","unstructured":"Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med. 2010;2(6):211\u201330. https:\/\/doi.org\/10.1002\/emmm.201000073.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"4959_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582\u201398. https:\/\/doi.org\/10.1038\/nrc.2016.73.","journal-title":"Nat Rev Cancer"},{"issue":"7015","key":"4959_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature03096","volume":"432","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332\u20137. https:\/\/doi.org\/10.1038\/nature03096.","journal-title":"Nature"},{"issue":"3","key":"4959_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","volume":"6","author":"A Orimo","year":"2005","unstructured":"Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion. Cell. 2005;6(3):335\u201348. https:\/\/doi.org\/10.1016\/j.cell.2005.02.034.","journal-title":"Cell"},{"issue":"12","key":"4959_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/nm.2512","volume":"17","author":"B Mateescu","year":"2011","unstructured":"Mateescu B, Batista L, Cardon M, Gruosso T, De Feraudy Y, Mariani O, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011;17(12):1627\u201335. https:\/\/doi.org\/10.1038\/nm.2512.","journal-title":"Nat Med"},{"issue":"3","key":"4959_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.022.","journal-title":"Cancer Cell"},{"key":"4959_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2013.12.007","volume":"25","author":"A Costa","year":"2014","unstructured":"Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol. 2014;25:23\u201332. https:\/\/doi.org\/10.1016\/j.semcancer.2013.12.007.","journal-title":"Semin Cancer Biol"},{"issue":"32","key":"4959_CR11","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pur\u00e9","year":"2018","unstructured":"Pur\u00e9 E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37(32):4343\u201357. https:\/\/doi.org\/10.1038\/s41388-018-0275-3.","journal-title":"Oncogene"},{"issue":"50","key":"4959_CR12","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212\u20137. https:\/\/doi.org\/10.1073\/pnas.1320318110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"4959_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0094.","journal-title":"Cancer Discov"},{"issue":"2","key":"4959_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, M\u00fcller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15\u2009+\u2009myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2020;10(2):232\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0644.","journal-title":"Cancer Discov"},{"issue":"9","key":"4959_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1384.","journal-title":"Cancer Discov"},{"issue":"1","key":"4959_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121\u201344. https:\/\/doi.org\/10.1111\/imr.12528.","journal-title":"Immunol Rev"},{"issue":"14","key":"4959_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411759","volume":"24","author":"N Bach","year":"2023","unstructured":"Bach N, Winzer R, Tolosa E, Fiedler W, Brauneck F. The clinical significance of CD73 in cancer. Int J Mol Sci. 2023;24(14):11759. https:\/\/doi.org\/10.3390\/ijms241411759.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4959_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/annonc\/mdx730","volume":"29","author":"L Buisseret","year":"2018","unstructured":"Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol. 2018;29(4):1056\u201362. https:\/\/doi.org\/10.1093\/annonc\/mdx730.","journal-title":"Ann Oncol"},{"issue":"23","key":"4959_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235878","volume":"13","author":"I Magagna","year":"2021","unstructured":"Magagna I, Gourdin N, Kieffer Y, Licaj M, Mhaidly R, Andre P, et al. CD73-mediated immunosuppression is linked to a specific fibroblast population that paves the way for new therapy in breast cancer. Cancers. 2021;13(23):5878. https:\/\/doi.org\/10.3390\/cancers13235878.","journal-title":"Cancers"},{"issue":"16","key":"4959_CR20","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","volume":"70","author":"B Zhang","year":"2010","unstructured":"Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 2010;70(16):6407\u201311. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1544.","journal-title":"Cancer Res"},{"issue":"6","key":"4959_CR21","first-page":"1341","volume":"17","author":"X Zhou","year":"2007","unstructured":"Zhou X, Zhi X, Zhou P, Chen S, Zhao F, Shao Z, et al. Effects of ecto-5\u2019-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep. 2007;17(6):1341\u20136.","journal-title":"Oncol Rep"},{"issue":"1","key":"4959_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42744-y","volume":"14","author":"L Buisseret","year":"2023","unstructured":"Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, et al. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial. Nat Commun. 2023;14(1):7018. https:\/\/doi.org\/10.1038\/s41467-023-42744-y.","journal-title":"Nat Commun"},{"key":"4959_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4330329","volume":"2022","author":"P Sun","year":"2022","unstructured":"Sun P, Zheng X, Li X. The effects of CD73 on gastrointestinal cancer progression and treatment. J Oncol. 2022;2022:4330329. https:\/\/doi.org\/10.1155\/2022\/4330329.","journal-title":"J Oncol"},{"key":"4959_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00832","volume":"8","author":"B Chen","year":"2020","unstructured":"Chen B, Chen J, Yang M, Yin Y, Xu Y. MKL1 mediates TGF-\u03b2 induced RhoJ transcription to promote breast cancer cell migration and invasion. Front Cell Dev Biol. 2020;8:832. https:\/\/doi.org\/10.3389\/fcell.2020.00832.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4959_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jso.23056.","volume":"106","author":"XR Wu","year":"2012","unstructured":"Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106(2):130\u20137. https:\/\/doi.org\/10.1002\/jso.23056.","journal-title":"J Surg Oncol"},{"issue":"12","key":"4959_CR26","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3748\/wjg.v19.i12.1912","volume":"19","author":"XX Lu","year":"2013","unstructured":"Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia-inducible factor-1\u03b1 in gastric carcinoma. World J Gastroenterol. 2013;19(12):1912\u20138. https:\/\/doi.org\/10.3748\/wjg.v19.i12.1912.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4959_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s12253-013-9648-7","volume":"19","author":"Q Yang","year":"2013","unstructured":"Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol Oncol Res. 2013;19(4):811\u20134. https:\/\/doi.org\/10.1007\/s12253-013-9648-7.","journal-title":"Pathol Oncol Res"},{"issue":"27","key":"4959_CR28","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.1073\/pnas.1222251110","volume":"110","author":"S Loi","year":"2013","unstructured":"Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013;110(27):11091\u20136. https:\/\/doi.org\/10.1073\/pnas.1222251110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4959_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85379-z","volume":"11","author":"N Petruk","year":"2021","unstructured":"Petruk N, Tuominen S, \u00c5kerfelt M, Mattsson J, Sandholm J, Nees M, et al. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Sci Rep. 2021;11(1):6035. https:\/\/doi.org\/10.1038\/s41598-021-85379-z.","journal-title":"Sci Rep"},{"issue":"21","key":"4959_CR30","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","volume":"75","author":"M Turcotte","year":"2015","unstructured":"Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015;75(21):4494\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3569.","journal-title":"Cancer Res"},{"issue":"1","key":"4959_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3892\/ol.2016.4652","volume":"12","author":"ZH Ren","year":"2016","unstructured":"Ren ZH, Yuan YX, Ji T, Zhang CP. CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma. Oncol Lett. 2016;12(1):556\u201362. https:\/\/doi.org\/10.3892\/ol.2016.4652.","journal-title":"Oncol Lett"},{"issue":"38","key":"4959_CR32","doi-asserted-by":"publisher","first-page":"61690","DOI":"10.18632\/oncotarget.11435","volume":"7","author":"ZH Ren","year":"2016","unstructured":"Ren ZH, Lin CZ, Cao W, Yang R, Lu W, Liu ZQ, et al. CD73 is associated with poor prognosis in HNSCC. Oncotarget. 2016;7(38):61690\u2013702. https:\/\/doi.org\/10.18632\/oncotarget.11435.","journal-title":"Oncotarget"},{"issue":"1","key":"4959_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14060-x","volume":"11","author":"M Yu","year":"2020","unstructured":"Yu M, Guo G, Huang L, Deng L, Chang CS, Achyut BR, et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. Nat Commun. 2020;11(1):515. https:\/\/doi.org\/10.1038\/s41467-019-14060-x.","journal-title":"Nat Commun"},{"issue":"6","key":"4959_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10585-007-9081-y","volume":"24","author":"X Zhi","year":"2007","unstructured":"Zhi X, Chen S, Zhou P, Shao Z, Wang L, Ou Z, et al. RNA interference of ecto-5\u2019-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis. 2007;24(6):439\u201348. https:\/\/doi.org\/10.1007\/s10585-007-9081-y.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"4959_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00432-007-0292-z","volume":"134","author":"L Wang","year":"2008","unstructured":"Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, et al. Ecto-5\u2019-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2008;134(3):365\u201372. https:\/\/doi.org\/10.1007\/s00432-007-0292-z.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"4959_CR36","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1111\/j.1349-7006.2010.01733.x","volume":"101","author":"X Zhi","year":"2010","unstructured":"Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang S, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 2010;101(12):2561\u20139. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01733.x.","journal-title":"Cancer Sci"},{"issue":"26","key":"4959_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107(26):1547\u201352. https:\/\/doi.org\/10.1073\/pnas.0908801107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4959_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/ajco.13450","volume":"18","author":"HR Choi","year":"2022","unstructured":"Choi HR, Oh HK, Park SH, Jeong YJ. Expression of CD73 is associated with tumor progression and intratumoral inflammation in breast cancer. Asia Pac J Clin Oncol. 2022;18(1):35\u201343. https:\/\/doi.org\/10.1111\/ajco.13450.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"4959_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-174","volume":"7","author":"JAW Chapman","year":"2007","unstructured":"Chapman JAW, Miller NA, Lickley HLA, Qian J, Christens-Barry WA, Fu Y, et al. Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment. BMC Cancer. 2007;7(1):174. https:\/\/doi.org\/10.1186\/1471-2407-7-174.","journal-title":"BMC Cancer"},{"issue":"3","key":"4959_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057773","volume":"8","author":"X Catteau","year":"2013","unstructured":"Catteau X, Simon P, Vanhaeverbeek M, No\u00ebl JC. Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast. PLoS One. 2013;8(3):e57773. https:\/\/doi.org\/10.1371\/journal.pone.0057773.","journal-title":"PLoS One"},{"issue":"15","key":"4959_CR41","doi-asserted-by":"publisher","first-page":"11550","DOI":"10.1158\/0008-5472.CAN-06-3149","volume":"66","author":"R Weinberg","year":"2006","unstructured":"Weinberg R, Mihich E. Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions. Cancer Res. 2006;66(15):11550\u20133. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3149.","journal-title":"Cancer Res"},{"key":"4959_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.609931","volume":"11","author":"R Turiello","year":"2020","unstructured":"Turiello R, Pinto A, Morello S. CD73: a promising biomarker in cancer patients. Front Pharmacol. 2020;11:609931. https:\/\/doi.org\/10.3389\/fphar.2020.609931.","journal-title":"Front Pharmacol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04959-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04959-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04959-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:53:15Z","timestamp":1780390395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04959-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4959"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04959-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional ethics and research review boards and is in accordance with Belgian and International law (Helsinki declaration) (Comit\u00e9 d\u2019\u00e9thique hospitalo-facultaire number 021\/406- Hopitaux Universitaires de Bruxelles- Facult\u00e9 de M\u00e9decine- Universit\u00e9 Libre de Bruxelles route de Lennik 808, 1070 Brussels, Belgium; clinical trial number 587). Patients signed a written informed consent upon admission to the hospital. Patients chose at admission whether to opt in or to opt out of providing consent, which affirms that physicians have the right to use surplus patient biological material for research. We have obtained informed consent from all patients for the use of residual tissue samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"837"}}